- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
- Interventions
- ampreloxetine, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 20
- States / cities
- Sun City, Arizona • La Jolla, California • Palo Alto, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 112
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- lenvatinib, pembrolizumab, saline placebo
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 794 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Duarte, California • La Jolla, California + 17 more
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
- Interventions
- pembrolizumab, placebo, cisplatin, 5-FU, radiotherapy, leucovorin, levoleucovorin, oxaliplatin
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 703 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 19
- States / cities
- Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more
- Conditions
- Colorectal Cancer
- Interventions
- favezelimab/pembrolizumab, regorafenib, TAS-102
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 441 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 15
- States / cities
- Washington D.C., District of Columbia • Marietta, Georgia • Louisville, Kentucky + 11 more
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 39
- States / cities
- Mobile, Alabama • Chandler, Arizona • Duarte, California + 33 more
- Conditions
- Parkinson Disease
- Interventions
- APL-130277, APO-go, Apokyn
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Boca Raton, Florida • Port Charlotte, Florida • Farmington Hills, Michigan
- Conditions
- Parkinson Disease
- Interventions
- Spinning Class, Yoga Class, Dance Class
- Behavioral
- Lead sponsor
- Premier Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Dayton, Ohio
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more
- Conditions
- Parkinson Disease, Early Parkinson's Disease
- Interventions
- P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg, Marketed Pramipexole ER
- Drug
- Lead sponsor
- Pharma Two B Ltd.
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 45
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more
- Conditions
- Carcinoma, Nonsquamous Non-small-cell Lung
- Interventions
- Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin, Olaparib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,003 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Muscle Shoals, Alabama • Burbank, California + 16 more
- Conditions
- Endometrial Neoplasms
- Interventions
- pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • La Jolla, California • Riverside, California + 28 more
- Conditions
- Metastatic Non-Small Cell Lung Cancer
- Interventions
- Pembrolizumab, Lenvatinib, Docetaxel
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 28
- States / cities
- Bakersfield, California • Fleming Island, Florida • Orange City, Florida + 24 more
- Conditions
- Parkinson Disease
- Interventions
- BHV-8000 10mg, BHV-8000 20 mg, Placebo
- Drug
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Irvine, California • Los Angeles, California + 21 more
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 27
- States / cities
- Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor
- Biological · Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 6
- States / cities
- Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more
- Conditions
- Parkinson Disease
- Interventions
- BIIB122, BIIB122-Matching Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 12
- States / cities
- San Francisco, California • Aurora, Colorado • Englewood, Colorado + 8 more
- Conditions
- Early Parkinson Disease (Early PD)
- Interventions
- Pramipexol Extended Release, Pramipexol Immediate Release, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 539 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Sun City, Arizona • La Jolla, California + 13 more
- Conditions
- Parkinson Disease
- Interventions
- Tavapadon, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 529 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 24 more
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- CVT-301, Observational cohort
- Drug · Other
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Fountain Valley, California • Panorama City, California + 10 more
- Conditions
- Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
- Interventions
- Dipraglurant, Placebo
- Drug
- Lead sponsor
- Addex Pharma S.A.
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Fresno, California • Irvine, California + 38 more
- Conditions
- Parkinson Disease
- Interventions
- Isradipine, Placebo (for Isradipine)
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 40 more
- Conditions
- Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
- Interventions
- favezelimab/pembrolizumab, pembrolizumab, lenvatinib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • New Brunswick, New Jersey + 5 more
- Conditions
- Lung Cancer
- Interventions
- Pembrolizumab, Epacadostat, Platinum-based chemotherapy, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 21
- States / cities
- Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension
- Interventions
- ampreloxetine
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 13
- States / cities
- Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more